Sugi Predict

Sugi Predict / Compounds / SCHEMBL1480335

SCHEMBL1480335

SCHEMBL1480335

CCn1cc(-c2ccc(Cl)cc2Cl)nc1/C=C/c1ccc(Br)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.40
▸ DHODH Q02127 1/20 0.36
▸ DPP4 P27487 2/20 0.35
▸ DPP8 Q6V1X1 2/20 0.35
▸ HSP90AA1 P07900 2/20 0.34
▸ HSP90AB1 P08238 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ GABRB2 P47870 1/20 0.34
▸ DPP9 Q86TI2 1/20 0.34
▸ MAOA P21397 1/20 0.33
▸ ALPL P05186 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480339 1.00 LMNA (0.40) LMNADHODHDPP4DPP8HSP90AA1
SCHEMBL1482170 0.89 MAPT (0.42) LMNADPP4DPP8HSP90AA1HSP90AB1
SCHEMBL1482165 0.89 MAPT (0.42) LMNADPP4DPP8HSP90AA1HSP90AB1
SCHEMBL1481527 0.88 ADORA2A (0.38) LMNADHODHDPP4DPP8KDM4E
SCHEMBL1481529 0.88 ADORA2A (0.38) LMNADHODHDPP4DPP8KDM4E
SCHEMBL1480782 0.87 RELA (0.42) LMNADPP4DPP8KDM4EMAPT
SCHEMBL1480780 0.87 RELA (0.42) LMNADPP4DPP8KDM4EMAPT
SCHEMBL1481849 0.86 TLR8 (0.43) KDM4EMAPTTDP1
SCHEMBL1481852 0.86 TLR8 (0.43) KDM4EMAPTTDP1
SCHEMBL1480642 0.86 MEN1 (0.45) LMNADPP4DPP8KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 — — US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 — — US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 — — US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 — — US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 — — EP disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 — — US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 — — US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ LMNA 4711/4885DHODH 568/4885DPP4 132/4885
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE LMNA 4379/4885DHODH 902/4885DPP4 115/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE LMNA 4379/4885DHODH 902/4885DPP4 115/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ LMNA 4711/4885DHODH 568/4885DPP4 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.